Vanderbilt Cyclopropylpiperidine M4 Antagonists - US12600726B2
Summary
The USPTO granted Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, covering cyclopropylpiperidine compounds useful as antagonists of muscarinic acetylcholine receptor M4 (mAChR M4). The patent includes 15 claims and covers methods of making the compounds, pharmaceutical compositions, and methods of treating disorders using the compounds. Vanderbilt University receives enforceable IP rights for this therapeutic compound class.
What changed
The USPTO issued Patent No. US12600726B2 to Vanderbilt University on April 14, 2026, granting enforceable intellectual property rights for cyclopropylpiperidine compounds acting as M4 muscarinic acetylcholine receptor antagonists. The patent covers 15 claims including the compound structures, methods of manufacture, pharmaceutical compositions, and methods of treating disorders using these antagonists.
Pharmaceutical companies and researchers developing M4 receptor-targeted therapies should monitor this patent grant to assess potential licensing needs or freedom-to-operate implications. Competitors working in the muscarinic receptor space may need to evaluate whether their compounds fall within the scope of these claims. The patent strengthens Vanderbilt University's intellectual property portfolio in the CNS/neurological therapeutics area.
What to do next
- Monitor patent status for potential licensing opportunities
- Review patent claims for freedom-to-operate considerations if developing related compounds
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antagonists of the muscarinic acetylcholine receptor M4
Grant US12600726B2 Kind: B2 Apr 14, 2026
Assignee
Vanderbilt University
Inventors
Craig W. Lindsley, Thomas M. Bridges, P. Jeffrey Conn, Aaron M. Bender, Darren W. Engers
Abstract
Disclosed herein are cyclopropylpiperidine compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (niAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders using the compounds and compositions.
CPC Classifications
C07D 487/04 C07D 401/12 C07D 401/14 C07D 405/14 C07D 409/14 C07D 413/14 C07D 417/14 C07D 493/08 C07B 2200/05
Filing Date
2018-07-12
Application No.
16629491
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.